FBR Capital Thinks Bellerophon’s Stock is Going to Recover

By George MacDonald

In a report released yesterday, Christopher James from FBR Capital reiterated an Outperform rating on Bellerophon (NASDAQ: BLPH), with a price target of $11. The company’s shares closed yesterday at $2.89, close to its 52-week low of $1.90.

James commented, “This morning, March 21, Bellerophon Therapeutics held its first earnings conference call to discuss its 4Q15 financial results and provide an update on the future development path for INOpulse. As a reminder, Bellerophon is developing INOpulse, an inhaled nitric oxide drug-device combination for the potential treatment of patients with pulmonary hypertension (PH). We highlight a few takeaways from the call: (1) Bellerophon recently received FDA approval under its SPA to use its improved Mark2 device and expects to initiate the first of two Phase III trials in patients with pulmonary arterial hypertension (PAH) at the beginning of 2Q16; (2) Bellerophon remains on track to initiate additional studies in PH patients with chronic obstructive pulmonary disease (PH-COPD) and idiopathic pulmonary fibrosis (PH-IPF) during 1H16; and (3) we continue to expect better compliance with the new lighter Mark2 device.”

Bellerophon has an analyst consensus of Moderate Buy.

The company has a one year high of $11.12 and a one year low of $1.90. Currently, Bellerophon has an average volume of 46.08k.

Unlike FBR Capital`s latest rating, based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2015, Jonathan Peacock, a the President & CEO of BLPH bought 20,300 shares for a total of $55,728.

According to TipRanks.com, James is ranked 0 out of 5 stars with an average return of -17.2% and a 30.4% success rate. James covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc., Asterias Biotherapeutics, and Oramed Pharmaceuticals.

Bellerophon Therapeutics LLC is a clinical-stage therapeutics company developing products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary and cardiac diseases.